Integrin Activator Compounds Enhancing T-Cell Anti-Cancer Activity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceutical compositions lack effective solutions for enhancing anti-cancer activity of nature T-cells by improving integrin binding, which is crucial for treating and reducing symptoms of diseases, maladies, and cancers.
Innovation Solution
Pharmaceutical compositions including N,N-disubstituted amide, carbamate, urea, and sulfonamide compounds that act as integrin activators, specifically targeting integrins such as α4β1, α4β7, α5β1, αLβ2, and αVβ3 to enhance their binding to ligands like VCAM-1, fibronectin, and vitronectin, thereby improving anti-cancer activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional pharmaceutical compositions are used, then general anti-cancer treatment is provided, but the anti-cancer activity of natural T-cells is not enhanced
Solution Approach 1:
The patent modifies the chemical structure of integrin-targeting compounds by varying substituents at specific positions (R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12) to optimize integrin binding affinity and T-cell activation. This includes changing functional groups such as amide, carbamate, urea, and sulfonamide moieties to enhance the reliability of anti-cancer activity while maintaining structural adaptability.
Solution Approach 2:
The patent employs composite molecular structures combining multiple functional groups (amide, carbamate, urea, sulfonamide) within single integrin activator molecules. These composite structures enable simultaneous interaction with integrins and enhancement of T-cell anti-cancer activity, resolving the contradiction between reliability of treatment and adaptability of binding.
2Adaptability or versatility
If integrin activators are designed to target multiple integrins, then binding versatility is improved, but molecular complexity increases
Solution Approach 1:
The patent designs integrin activator molecules with universal binding capabilities across multiple integrin subtypes (α4β1, α4β7, α5β1, αLβ2, αVβ3) through common structural motifs. The core molecular framework remains consistent while allowing substituent variations to accommodate different integrin specificities, achieving multi-functionality without proportionally increasing complexity.
Solution Approach 2:
The patent introduces specific substituent groups at localized positions (R1-R12) on the integrin activator molecule to confer specificity for different integrin subtypes. This allows the majority of the molecular structure to remain simple and consistent, while local modifications provide the necessary versatility for targeting multiple integrins.
3Reliability
If integrin binding affinity is increased to improve T-cell infiltration, then anti-cancer efficacy is enhanced, but selectivity for tumor tissue may be reduced
Solution Approach 1:
The patent optimizes binding affinity parameters by adjusting substituent groups to achieve high-affinity binding to tumor-associated integrins while maintaining selectivity. Specific substitutions at R1-R12 positions fine-tune the balance between affinity and selectivity, ensuring enhanced anti-cancer efficacy without excessive off-target binding.
Data Source
AI summary
Pharmaceutical compositions including one or more integrin activators capable of capable of improving the anti-cancer activity of nature t-cells, wherein the integrin activators target integrins including, but not limited to, α4β1, α4β7, α5β1, αLβ2 and/or αVβ3 improving binding to their respective ligands including, but not limited to, VCAM-1, fibronectin, MAdCAM-1, ICAM-1, ICAM-2, and/or vitronectin, wherein the compositions treat, ameliorate, and/or reduce symptoms of diseases, maladies, and cancers, and methods for making and using for preventing, treating, ameliorating, and/or reducing symptoms of cancerous tumors, cancerous solid tumors, other cancerous growth, and/or other cancerous.